Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Gains from Investment Securities (2023 - 2025)

Historic Gains from Investment Securities for Immunocore Holdings (IMCR) over the last 3 years, with Q3 2025 value amounting to $2.1 million.

  • Immunocore Holdings' Gains from Investment Securities rose 45530.82% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year increase of 45751.63%. This contributed to the annual value of -$1.8 million for FY2024, which is 12049.54% down from last year.
  • Immunocore Holdings' Gains from Investment Securities amounted to $2.1 million in Q3 2025, which was up 45530.82% from $2.0 million recorded in Q2 2025.
  • In the past 5 years, Immunocore Holdings' Gains from Investment Securities ranged from a high of $9.5 million in Q1 2024 and a low of -$1.1 million during Q2 2024
  • Over the past 3 years, Immunocore Holdings' median Gains from Investment Securities value was $110000.0 (recorded in 2023), while the average stood at $1.2 million.
  • Within the past 5 years, the most significant YoY rise in Immunocore Holdings' Gains from Investment Securities was 443541.73% (2024), while the steepest drop was 34795.45% (2024).
  • Quarter analysis of 3 years shows Immunocore Holdings' Gains from Investment Securities stood at $757000.0 in 2023, then plummeted by 140.03% to -$303000.0 in 2024, then skyrocketed by 784.82% to $2.1 million in 2025.
  • Its Gains from Investment Securities stands at $2.1 million for Q3 2025, versus $2.0 million for Q2 2025 and -$509000.0 for Q1 2025.